Print Page | Close Window

2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
12/08/14GTx to Present Results on Enobosarm 9mg in Women with Metastatic Breast Cancer at 2014 San Antonio Breast Cancer Symposium
Company to Host Investor Meeting to Review Breast Cancer Program and Clinical Results MEMPHIS, Tenn.--(BUSINESS WIRE)--Dec. 8, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that the results from its positive proof of concept Phase 2 clinical trial evaluating enobosarm 9mg in post-menopausal women with estrogen receptor (ER) positive and androgen receptor (AR) positive metastatic breast cancer will be featured in a poster presentation at the ... 
Printer Friendly Version
11/17/14GTx Announces Closing of $43.4 Private Placement
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 17, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx sold 64,311,112 immediately separable units, comprised of an aggregate of 64,311,112 newly-issued shares of common stock and warrants to purchase up to 64,311,112 additional shares of common stock, for an aggregat... 
Printer Friendly Version
11/12/14GTx Announces Webcast of Corporate Presentation at the Stifel 2014 Healthcare Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 12, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 18, 2014, at the Stifel 2014 Healthcare Conference in New York City. The GTx presentation will begin at 3:00 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company web... 
Printer Friendly Version
11/10/14GTx Provides Corporate Update and Reports Third Quarter 2014 Financial Results
Company’s primary corporate focus targets the androgen receptor in women with advanced breast cancer Closing of recently announced private placement will provide cash through 2016 and key breast cancer milestones Conference call today at 9:00 a.m. ET MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 10, 2014-- GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter ended September 30, 2014 and highlighted recent acc... 
Printer Friendly Version
11/10/14GTx Announces $43.4 Million Private Placement
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 10, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a securities purchase agreement for the sale of approximately $43.4 million of its common stock and warrants to purchase common stock in a private placement. The group of accredited investors includes Biotechnology Value Fund, L. P. and other affiliates of BVF Partners L.P., certain existing GTx stockholders and certain members of the GTx ... 
Printer Friendly Version
11/03/14GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call and Webcast
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov. 3, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2014 financial results on Monday, November 10 at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day. To listen to the conference call, please dial: 877-415-31... 
Printer Friendly Version
08/07/14GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Aug. 7, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on August 13, 2014, at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference in New York City. The GTx presentation will begin at 2:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be availabl... 
Printer Friendly Version
08/05/14GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--Aug. 5, 2014-- GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2014. The Company also highlighted clinical development progress with enobosarm, an oral selective androgen receptor modulator, as well as progress with GTx-758, its oral nonsteroidal selective estrogen receptor alpha agonist, being studied for secondary hormonal therapy in men with castration-resistant p... 
Printer Friendly Version
07/22/14GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014
MEMPHIS, Tenn.--(BUSINESS WIRE)--Jul. 22, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets. Similar to the previous quarter, the Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company de... 
Printer Friendly Version
06/02/14GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer
--Study of Targeted Therapy Met Primary Endpoint with 35 Percent of Patients Achieving Clinical Benefit Response-- MEMPHIS, Tenn.--(BUSINESS WIRE)--Jun. 2, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen recept... 
Printer Friendly Version
05/22/14GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 22, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 4, 2014, at the Jefferies 2014 Global Healthcare Conference in New York City. The GTx presentation will begin at 1:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company ... 
Printer Friendly Version
05/19/14GTx to Present Clinical Data on Enobosarm in Breast Cancer and NSCLC at ASCO 2014 Annual Meeting
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 19, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that clinical data from two separate enobosarm clinical development programs will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 - June 3, 2014, in Chicago, Illinois. Enobosarm 9mg: for the potential treatment of androgen receptor and estrogen receptor positive metastatic breast cancer ... 
Printer Friendly Version
05/08/14GTx Provides Corporate Update and Reports First Quarter 2014 Financial Results
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 8, 2014-- GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the first quarter of 2014. Clinical updates Enobosarm (GTx-024) 3mg, an oral selective androgen receptor modulator, being developed for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer: Following GTx’s announcement in August 2013 that the POWER1... 
Printer Friendly Version
04/24/14GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014
MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 24, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2014 financial results press release will be Thursday, May 8, 2014, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate througho... 
Printer Friendly Version
04/04/14GTx Announces Departure of CEO
- Dr. Mitchell Steiner steps down as CEO and Vice Chairman of the Board - - Marc Hanover, GTx’s President and COO, named interim CEO - MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 4, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that Mitchell S. Steiner, its vice chairman and chief executive officer (CEO) and a co-founder of the company, is leaving GTx to pursue other business interests. Dr. Steiner has stepped down from his roles as CEO an... 
Printer Friendly Version
03/06/14GTx, Inc. Announces Closing of Private Placement
MEMPHIS, Tenn.--(BUSINESS WIRE)--Mar. 6, 2014-- GTx, Inc. (NASDAQ: GTXI) announced today that it closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx issued 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 newly-issued shares of common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The purchasers ... 
Printer Friendly Version
03/05/14GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Mar. 5, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 11, 2014 at the 26th Annual ROTH Conference in Dana Point, CA. The GTx presentation will begin at 1:00 p.m. EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website unt... 
Printer Friendly Version
03/04/14GTx Provides Corporate Update and Reports 2013 Financial Results
Plans to file MAA for enobosarm 3mg by first quarter 2015 MEMPHIS, Tenn.--(BUSINESS WIRE)--Mar. 4, 2014-- GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013. Clinical updates Enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, being developed for the prevention and treatment of muscle wasting in patients with advanced non-small c... 
Printer Friendly Version
03/04/14GTx, Inc. Announces Pricing of Private Placement
MEMPHIS, Tenn.--(BUSINESS WIRE)--Mar. 4, 2014-- GTx, Inc. (NASDAQ: GTXI) announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTx’s Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 1... 
Printer Friendly Version
02/26/14GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 26, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 5, 2014 at the Cowen and Company 34th Annual Health Care Conference in Boston. The GTx presentation will begin at 8.00 a.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company ... 
Printer Friendly Version
02/18/14GTx, Inc. To Host Fourth Quarter and Full Year 2013 Financial Results Conference Call and Webcast
MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 18, 2014-- GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company’s fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day. To listen to the conference call, please dial: ... 
Printer Friendly Version
02/04/14GTx Announces Webcast of Corporate Presentation at Bio CEO & Investor Conference
MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 4, 2014-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on February 10, 2014 at the Bio CEO & Investor Conference in New York City. The GTx presentation will begin at 3:30 p.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company web... 
Printer Friendly Version
01/29/14Preliminary findings from the Phase 2 clinical trial of GTx-758 in men with castration resistant prostate cancer to be presented at ASCO Genitourinary Cancer Symposium
Enrollment of the 125mg cohort is completed and 250mg cohort is currently enrolling MEMPHIS, Tenn.--(BUSINESS WIRE)--Jan. 29, 2014-- GTx, Inc. (NASDAQ: GTXI) announced today that Dr. Evan Yu, Associate Professor of Medicine and Oncology at the University of Washington School of Medicine and Clinical Trials Director, Genitourinary Oncology Clinical Trials Core, Seattle Cancer Care Alliance, will present preliminary findings from the Company’s P... 
Printer Friendly Version